What the phase 2 papers recorded, in the terms they used

Published 24 October 2026 · REVIVE LAB UAE Research Desk · 5 min read
In both phase 2 trials the most frequently reported adverse events were gastrointestinal — nausea, diarrhoea, vomiting and constipation — mostly mild to moderate, dose-related, and concentrated during the escalation period. The NEJM paper also reported dose-related increases in heart rate that peaked early and declined thereafter. Discontinuation for adverse events was more common at higher doses.

How adverse events are recorded

Every untoward event in a participant is recorded regardless of presumed cause, graded for severity, and assessed for relationship to the compound. Events are reported by group so that the rate in active arms can be compared against placebo.

This is what allows a reader to distinguish an event the compound causes from one that happens to people in trials.

What was reported

Gastrointestinal events were the most common in both trials and tracked dose. Most were mild or moderate and occurred during dose escalation. The NEJM trial reported an early increase in heart rate that was dose-related and attenuated over time. The Lancet trial reported no severe hypoglycaemia in retatrutide groups.

Discontinuation because of adverse events increased with dose in both trials, and the papers give the proportions by group.

What phase 2 cannot tell you

A few hundred participants over 36 to 48 weeks can characterise common events and their relationship to dose. It cannot detect rare events, and it cannot speak to long-term exposure. Those are what phase 3 and post-approval surveillance exist to assess.

A phase 2 safety profile is a description of what was seen in that population over that period, and the papers present it as such.

Supply

Retatrutide is supplied by REVIVE LAB UAE as an investigational research material for laboratory use only, with identity by mass spectrometry and purity by HPLC for the batch. It is not approved for any use anywhere, and no dosing, administration or protocol guidance is provided.

What it costs

FormatStrengthPriceAvailability
Retatrutide Pack20 mgAED 1010In stock

Delivery is AED 40 flat and free on orders over AED 700. Payment is cash on delivery anywhere in the UAE, or USDT (TRC20) in advance, which takes 5% off the order total.

Frequently asked

How adverse events are recorded?

Every untoward event in a participant is recorded regardless of presumed cause, graded for severity, and assessed for relationship to the compound. Events are reported by group so that the rate in active arms can be compared against placebo.

Does REVIVE LAB UAE provide dosing guidance?

No. REVIVE LAB UAE supplies research materials and provides no dosing, administration or protocol guidance of any kind. Every product is sold for laboratory research use only and is not for human or veterinary consumption.

How fast is delivery in the UAE?

Stock is held in Dubai. An order confirmed before 4 PM Dubai time is dispatched the same working day, reaching Dubai and Abu Dhabi the same day and the remaining emirates within 24 hours. Delivery is AED 40 flat and free over AED 700.

Retatrutide Pack — in stock, dispatched from Dubai
HPLC-verified, lot certificate on every carton, 24-hour delivery nationwide. Browse the catalogue → All peptides UAE

Related reading

Supplied for laboratory research use only. Not for human or veterinary consumption. REVIVE LAB UAE provides no dosing, administration or protocol guidance.